Loading...
•
Jun 30, 2023
Cencora Q3 2023 Earnings Report
Revenue increased by 11.5% year-over-year, with GAAP diluted EPS at $2.35 and adjusted diluted EPS at $2.92. Adjusted diluted EPS guidance was raised to $11.85 to $11.95 for fiscal year 2023.
Key Takeaways
Cencora reported a strong Q3 2023 with revenue reaching $66.9 billion, an 11.5% increase year-over-year. GAAP diluted EPS was $2.35, and adjusted diluted EPS was $2.92. The company raised its adjusted diluted EPS guidance for fiscal year 2023 to a range of $11.85 to $11.95.
Revenue increased 11.5% year-over-year to $66.9 billion.
GAAP diluted EPS was $2.35, compared to $1.92 in the prior year.
Adjusted diluted EPS increased 11.5% to $2.92 from $2.62 in the prior year.
Adjusted diluted EPS guidance raised to $11.85 to $11.95 for fiscal year 2023.
Cencora
Cencora
Forward Guidance
AmerisourceBergen is updating its fiscal year 2023 financial guidance to primarily reflect its strong performance to date and updated foreign currency translation rates.
Positive Outlook
- Revenue growth to be at least 8 percent, up from the previous range of 6 to 8 percent.
- U.S. Healthcare Solutions revenue growth to be at least 9 percent, up from the previous range of 7 to 8 percent.
- International Healthcare Solutions revenue growth to be in the range of 1 to 4 percent, up from the previous range of a 3 percent decline to flat.
- Adjusted Diluted Earnings Per Share to be in the range of $11.85 to $11.95, representing growth of 7 to 8 percent, raised from the previous range of $11.70 to $11.90.
- Adjusted free cash flow to be at least $2 billion, from the previous guidance of approximately $2 billion.